Welcome
 Ahmad Zia “Lodin”
 M.Umar Farooq Khan
 Habibullah
 Introduction
 History
 Mission and Vision
 Organization & Culture
 Strategy & Managing Change
 Global Prospective
 SWOT Analysis
 Conclusion
 GlaxoSmithKline (GSK) is a British
multinational pharmaceutical, biologics, vaccin
es and consumer healthcare company
headquartered in Brent ford, London. As of
March 2014, it was the world's sixth-largest
pharmaceutical company after Johnson &
Johnson, Novartis , Hoffmann-La Roche, Pfizer,
and Sanofi, measured by 2013 revenue.
 GlaxoSmithKline plc is a public limited company
incorporated on 6th December 1999 under
English law. Its shares are listed on the London
Stock Exchange and the New York Stock
Exchange.
 On 27th December 2000 the company acquired
Glaxo Wellcome plc and SmithKline Beecham plc,
both English public limited companies, by way of
a scheme of arrangement for the merger of the
two companies.
 History GSK and its subsidiary and associated
undertakings constitute a major global healthcare
group engaged in the creation, discovery,
development, manufacture and marketing of
pharmaceutical and consumer health-related
products.
 GSK has its corporate head office in London and
has its US headquarters in Research Triangle Park,
North Carolina, with operations in some 120
countries, and products sold in over 150 countries.
MissionandVision
 ‘’Improve the quality of human life by enabling
people to do more, feel better and live longer’’.
 We carry out our business with the enthusiasm
of entrepreneurs, excited by the constant
search for innovation.
 We also have a strong culture of performance
achieved with integrity.
 We are confident of attaining our set goals
because our people bring to the workplace an
attitude of passion and positive attitude.
Organization
BOD
CEO
Deout Chairman
Trade net Dept
Sales Management
Dept
Quality Control Dept Finance Dept
Human resources
Dept
Marketing
Management Dept
Advisory committee
on administration
development
Executive Directors
International Trade
Ins
General
Administration Dept
Planning and finance
Dept
Overseas & Domestic
Branch Office
National
Sales Dept
Provisional
sales Dept
Area Sales
Dept
Product
Line Q.C
Dept
Product
Q.C
Dept
Audit
Dept
Strategic
Management
Dept
Product
Management
Dept
Selection &
Recruitment
Dept
Executive Level
Director Level
Manager Level
Staff
 The main challenge for GSK;
 Use of Un-ethical practices in the
market
But as GSK is a trustworthy Multi National brand
(Controlled from UK).
Has a developed an Anti Bribery department.
Customer has a trust on GSK.
For making this trust even stronger & assuring
transparency, The MRs (Medical Representative) are
given no Sales targets to avoid the use of unfair
sales purposes in the lower staff.
 Respect people
 Patient focus
 Transparency
 Integrity
 In GSK, MR has the same respect as that of
the MD.
 Empowerment of the staff & Team work
 In market we have to highlight the plus
points of our product and the negatives
of the competitors.
 For example:
competitive products.
 Both are used for Respiratory Tract
Infections.
 Why people resist CHANGE?
 Lack of expertise is the main reason.
 GSK follows the Top down Bottom up design.
 GSK has same basic strategies all over the
world. But the secondary strategies are
aligned with the market. As we believe on
the policy of,
 “Think Globally
 Act Locally”
 GSK has the main focus on emerging markets
(Mainly China & other Asian countries)
 While our products can mainly be divided
into:
 Innovative Products More investment, higher
profitability & are the future of the Co.
 Mature Products Not much Investments. E.g.
Ampiclox
 Classical Products Big volumes but still have
less growth as compared to innovative
products. Lesser investments.
Strengths
 Strong management team.
 Large market share.
 Majority research based products in
Pakistan.
 Wide range of products.
 Less checking on the sales representatives
for their working in the field.
 High growth rate in emerging market of
pharma business.
 One of the good brand names in pharma
industry.
 GSK can be able to cash its name in baby
foods.
 Lower cost competitors or imports like
Chinese and Indian medicines etc
 Un-ethical practices while GSK have strong
SOPs.
 Mighty company so lower growths.
 Instability of the country .
Working in a competitive & the market where
un-ethical practices are common is very hard.
But still continuous hard work on the behavior
and values of the organization and its
employees can be fruitful, i-e Expanding
profits.
Thank you
Glaxo smith kline

Glaxo smith kline

  • 1.
  • 3.
     Ahmad Zia“Lodin”  M.Umar Farooq Khan  Habibullah
  • 4.
     Introduction  History Mission and Vision  Organization & Culture  Strategy & Managing Change  Global Prospective  SWOT Analysis  Conclusion
  • 5.
     GlaxoSmithKline (GSK)is a British multinational pharmaceutical, biologics, vaccin es and consumer healthcare company headquartered in Brent ford, London. As of March 2014, it was the world's sixth-largest pharmaceutical company after Johnson & Johnson, Novartis , Hoffmann-La Roche, Pfizer, and Sanofi, measured by 2013 revenue.
  • 6.
     GlaxoSmithKline plcis a public limited company incorporated on 6th December 1999 under English law. Its shares are listed on the London Stock Exchange and the New York Stock Exchange.  On 27th December 2000 the company acquired Glaxo Wellcome plc and SmithKline Beecham plc, both English public limited companies, by way of a scheme of arrangement for the merger of the two companies.
  • 7.
     History GSKand its subsidiary and associated undertakings constitute a major global healthcare group engaged in the creation, discovery, development, manufacture and marketing of pharmaceutical and consumer health-related products.  GSK has its corporate head office in London and has its US headquarters in Research Triangle Park, North Carolina, with operations in some 120 countries, and products sold in over 150 countries.
  • 8.
  • 9.
     ‘’Improve thequality of human life by enabling people to do more, feel better and live longer’’.
  • 10.
     We carryout our business with the enthusiasm of entrepreneurs, excited by the constant search for innovation.  We also have a strong culture of performance achieved with integrity.  We are confident of attaining our set goals because our people bring to the workplace an attitude of passion and positive attitude.
  • 11.
  • 12.
    BOD CEO Deout Chairman Trade netDept Sales Management Dept Quality Control Dept Finance Dept Human resources Dept Marketing Management Dept Advisory committee on administration development Executive Directors International Trade Ins General Administration Dept Planning and finance Dept Overseas & Domestic Branch Office National Sales Dept Provisional sales Dept Area Sales Dept Product Line Q.C Dept Product Q.C Dept Audit Dept Strategic Management Dept Product Management Dept Selection & Recruitment Dept
  • 13.
  • 14.
     The mainchallenge for GSK;  Use of Un-ethical practices in the market But as GSK is a trustworthy Multi National brand (Controlled from UK). Has a developed an Anti Bribery department. Customer has a trust on GSK. For making this trust even stronger & assuring transparency, The MRs (Medical Representative) are given no Sales targets to avoid the use of unfair sales purposes in the lower staff.
  • 15.
     Respect people Patient focus  Transparency  Integrity  In GSK, MR has the same respect as that of the MD.  Empowerment of the staff & Team work
  • 17.
     In marketwe have to highlight the plus points of our product and the negatives of the competitors.  For example: competitive products.  Both are used for Respiratory Tract Infections.
  • 18.
     Why peopleresist CHANGE?  Lack of expertise is the main reason.  GSK follows the Top down Bottom up design.
  • 19.
     GSK hassame basic strategies all over the world. But the secondary strategies are aligned with the market. As we believe on the policy of,  “Think Globally  Act Locally”  GSK has the main focus on emerging markets (Mainly China & other Asian countries)
  • 20.
     While ourproducts can mainly be divided into:  Innovative Products More investment, higher profitability & are the future of the Co.  Mature Products Not much Investments. E.g. Ampiclox  Classical Products Big volumes but still have less growth as compared to innovative products. Lesser investments.
  • 21.
    Strengths  Strong managementteam.  Large market share.  Majority research based products in Pakistan.  Wide range of products.
  • 22.
     Less checkingon the sales representatives for their working in the field.
  • 23.
     High growthrate in emerging market of pharma business.  One of the good brand names in pharma industry.  GSK can be able to cash its name in baby foods.
  • 24.
     Lower costcompetitors or imports like Chinese and Indian medicines etc  Un-ethical practices while GSK have strong SOPs.  Mighty company so lower growths.  Instability of the country .
  • 25.
    Working in acompetitive & the market where un-ethical practices are common is very hard. But still continuous hard work on the behavior and values of the organization and its employees can be fruitful, i-e Expanding profits.
  • 26.